Carrier-free nanoprodrug for p53-mutated tumor therapy via concurrent delivery of zinc-manganese dual ions and ROS

Human cancers typically express a high level of tumor-promoting mutant p53 protein (Mutp53) with a minimal level of tumor-suppressing wild-type p53 protein (WTp53). In this regard, inducing Mutp53 degradation while activating WTp53 is a viable strategy for precise anti-tumor therapy. Herein, a new c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jinping, Qu, Chang, Shao, Xinyue, Song, Guoqiang, Sun, Jingyu, Shi, Donghong, Jia, Ran, An, Hailong, Wang, Hongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218170/
https://www.ncbi.nlm.nih.gov/pubmed/35784636
http://dx.doi.org/10.1016/j.bioactmat.2022.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218170/
https://www.ncbi.nlm.nih.gov/pubmed/35784636
http://dx.doi.org/10.1016/j.bioactmat.2022.06.005

Ejemplares similares